Docking phospholipase A2 on membranes using electrostatic potential-modulated spin relaxation magnetic resonance.

Y Lin; R Nielsen; D Murray; W L Hubbell; C Mailer; B H Robinson; M H Gelb

doi:10.1126/science.279.5358.1925

Home/Archive/PubMed

PubMed · 9506941

Docking phospholipase A2 on membranes using electrostatic potential-modulated spin relaxation magnetic resonance.

Y Lin·R Nielsen·D Murray·W L Hubbell·C Mailer·B H Robinson·M H Gelb

View original source ↗Export metadata ↓

Abstract

A method involving electron paramagnetic resonance spectroscopy of a site-selectively spin-labeled peripheral membrane protein in the presence and absence of membranes and of a water-soluble spin relaxant (chromium oxalate) has been developed to determine how bee venom phospholipase A2 sits on the membrane. Theory based on the Poisson-Boltzmann equation shows that the rate of spin relaxation of a protein-bound nitroxide by a membrane-impermeant spin relaxant depends on the distance (up to tens of angstroms) from the spin probe to the membrane. The measurements define the interfacial binding surface of this secreted phospholipase A2.

Explore related subjects

Bee Venoms Binding Sites Chromates Electron Spin Resonance Spectroscopy Glycerophospholipids Liposomes Membrane Proteins Membranes, Artificial Models, Molecular Mutation Oxalates Phosphatidic Acids Phospholipases A Phospholipases A2 Spin Labels Surface Properties Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Y Lin, R Nielsen, D Murray, W L Hubbell, C Mailer, B H Robinson, M H Gelb. 1998-03-20. Docking phospholipase A2 on membranes using electrostatic potential-modulated spin relaxation magnetic resonance.. https://doi.org/10.1126/science.279.5358.1925

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

The molecular mechanism of bee venom phospholipase A2 inactivation by bolinaquinone.

The molecular basis of the inactivation of bee venom PLA2 by the marine natural product bolinaquinone (BLQ) was studied by several spectral techniques (CD, fluorescence, and NMR spectroscopy, mass spectrometry), biomimetic reactions, and molecular modeling. Our data suggest competitive inhibition based on a BLQ-PLA2 noncovalent molecular recognition. However, BLQ is also able to react selectively with Lys133 through conjugate addition followed by a beta elimination. The biological implications of both the covalent and noncovalent molecular events are discussed.

Bee Venoms↗

PubMed2006

Complementary and alternative medicine: is there a role in multiple sclerosis?

Despite effective conventional therapies for multiple sclerosis (MS), many people with MS explore complementary and alternative medicine (CAM) therapies for their symptoms. Common CAM therapies that people use include dietary modification, nutritional and herbal supplementation, and mind-body therapies. There is a revival of interest among MS researchers about the therapeutic potential of low-fat diet and essential fatty acid supplementation in MS. The efficacy of specific vitamin supplementation remains unclear. Recently, cannabis and yoga have been studied in more controlled studies and have provided evidence that they may have some benefit. The research on CAM therapies in MS is still exploratory, but considering peoples' interest and common use of these therapies, further research in this area is clearly warranted.

Bee Venoms↗

PubMed2006

Osteopontin: a potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses.

Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinued therapy for 3-6 years as compared with the untreated group. A significantly higher level of serum OPN was found in the completed treatment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom. These findings together with the fact that OPN is involved in Th1-associated immune response strongly suggest a role of OPN as a functional biomarker for VIT.

Bee Venoms↗